Meeting
2023 ASCO Genitourinary Cancers Symposium
Characteristics and outcomes for patients (pts) with metastatic small cell urothelial carcinoma (mSCUC).
Authors
Nathaniel R. Wilson
University of Texas Health Science Center at Houston, Houston, TX
Nathaniel R. Wilson , Jaanki Khandelwal , Lianchun Xiao , Amishi Yogesh Shah , Jianjun Gao , Sangeeta Goswami , Craig A. Kovitz , Charles Guo , Bogdan Czerniak , Christopher Logothetis , Paul Gettys Corn , Nizar M. Tannir , Arlene O. Siefker-Radtke , Omar Alhalabi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 522)
DOI
10.1200/JCO.2023.41.6_suppl.522
Abstract #
522
Poster Bd #
L5
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
A phase II trial of regorafenib for advanced urothelial cancer (aUC) following prior chemotherapy.
First Author: Gurudatta Naik
Poster
2015 Genitourinary Cancers Symposium
Second-line chemotherapy for metastatic urothelial cell carcinoma: Pooled analysis and construction of a prognostic model.
First Author: Samer Salah
Poster
2024 ASCO Genitourinary Cancers Symposium
Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).
First Author: Evangelia Vlachou
Poster
2023 ASCO Genitourinary Cancers Symposium
Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC).
First Author: Vadim S Koshkin